GLPGF News and Press, Galapagos Genomics Ord From 02/18/20

Source: Barron's Gilead ( GILD ) reported a Q4 revenue of $5.88 billion, Non-GAAP EPS of $1.30 and GAAP EPS of $2.12. The stock is flat post-earnings. I have been bearish on Gilead for a few years now. The company's top line has gone through fits and starts and it will likely continue th...

Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Revisiting Our Revised Security Selection Method Since June 2017, I've run a Marketplace service which has an " investing with a helmet on " approach: I present concentrated portfolios where each security is he...

Ziopharm Oncology ( ZIOP ) announced its plan to issue equity shares. The company reported that it plans to issue nearly 27.8 million shares, not including underwriters’ overallotment which will likely result in the issue of additional 4.2 million shares. The issue will be priced at $...

By Callum Turcan Data by YCharts Image Shown: Shares of Gilead Sciences Inc. ( GILD ) have come under immense pressure since mid-2015, however, with the company's revenues now stabilizing Gilead's outlook is getting brighter. Gilead Sciences Inc. recently delivered some good news as ...

Gilead Sciences (NASDAQ: GILD ) is an $80 billion American biotechnology company that researches, develops, and commercializes drugs. The company is renowned for curing Hepatitis C and its leading HIV treatments. As we’ll see throughout this article, Gilead Sciences’ impressive ...

Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...

Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Revisiting Our Revised Security Selection Method Since June 2017, I've run a Marketplace service which has an " investing with a helmet on " approach: I present concentrated portfolios where each security is he...

Gilead Tests Potential Ebola Treatment for Coronavirus Gilead Sciences ( GILD ) announced that it is currently in the process of evaluating the use of its experimental Ebola candidate, Nuc inhibitor GS-5734, for treating 2019-nCov infection. The company is currently engaged in active discu...

Source: Barron's Gilead ( GILD ) has been delivering uneven revenue growth over the last few quarters. Q2 2019 results showed promise, yet they followed an 8% sequential revenue decline in Q1. Gilead is chugging along, but I consider the stock a sell until it can deliver consistent top lin...

Source: Barron's Gilead ( GILD ) reports Q2 earnings July 30th. Analysts expect revenue of $5.51 billion and EPS of $1.72. The revenue estimate implies 4% growth sequentially. Investors should focus on the following key items: HCV Could Show Signs Of Life Gilead has experienced a ste...